Biomedical subjects

L W He

Publications and source records attributed to L W He.

5 recordsLinked to original sources

PubMed1995

[Amplification of oncogenes HER2, mdm-2 and myc in breast cancer determined by modified competitive PCR].

The amplification of oncogenes HER2, mdm-2 and myc was determined with a modified competitive PCR. The HER2, mdm-2 and myc genes were found to amplify in 5, 6 and 6 out of 15 patients with breast cancer respectively. The amplification of HER2 and mdm-2 correlated with advanced tumors and lymph node involvement respectively, indicating that the amplification of the oncogenes is a useful indicator for the prognosis of patients with breast cancer and for the study of the biological behaviors of tumors. This modified non-radioactive competitive PCR is simple to handle (even for DNA samples with low quantity and low quality), and accurate for measuring the copy numbers of genes.

Base Sequence↗

PubMed1994

[Vitrectomy under temporary keratoprosthesis].

In vitreoretinal disorders complicated by corneal opacity, a temporary keratoprosthesis device is placed into a trephined opening in the cornea to provide a clear stable view which permits the performance of pars plana vitrectomy and immediately following the vitrectomy, the keratoprosthesis is replaced by a corneal graft. Using this technique, we have saved blind eyes with corneal and vitreoretinal disorders in one surgical procedure, being a new approach for rehabilitation of eye sight. Since 1990, the operation has been performed on 10 patients of whom 9 obtained satisfactory results. They were the patients who had been impossible to be saved by other methods and had been abandoned. The patient with the best result had been followed for 15 months and his visual acuity achieved and maintained 0.3. In six cases, the operation was combined with multiple procedures in the vitreous, such as gas fluid exchange, internal drainage of subretinal fluid, injection of silicone oil, etc. to facilitate the reattachment of the complicated retinal detachment.

Cornea↗

PubMed1994

[Loss of heterozygosity at different chromosomes in patients with breast cancer].

The loss of heterozygosity (LOH) at chromosomes 3p24, 7q31, 16q24.3 and 17p13.1 was measured in 15 patients with breast cancer by means of polymerase chain reaction (PCR)-restriction fragment length polymorphisms (RFLP) or PCR-CA repeat analysis. In 36%, 36%, 50% and 56% of the informative cases, LOH was detected at 3p24, 7q31, 16q24.3 and 17p13.1 loci, respectively. All the LOH at 3p24 or 7q31 happened in stage II or III, 67% of the LOH at 3p24 or 7q31 happened in the cases with lymph node metastasis, and 67% of the LOH at 3p24 or 7q31 were found in estrogen receptor negative patients. This finding shows that the measurement of LOH at 3p24 and 7q31 may be an useful predicting marker for the prognosis of patients with breast cancer. The high percent of LOH at these four loci may also indicate the possibility of the existence of tumor suppressor genes for breast cancer.

Adult↗

PubMed1992

[Preliminary studies on c-erbB-2 protooncogene in breast cancer].

c-erbB-2 protooncogene amplification was analyzed with Southern blot technique in 50 breast cancer patients in an attempt to correlate the results with the prognosis. The median follow-up was 59 months. Amplification was found in 15/50 (30%) of these patients including two cases of rearrangement. A highly statistically significant difference was found in postoperative survivals of patients with or without c-erbB-2 amplification (P less than 0.005). When patients were divided into groups by stage, nodal status, tumor size and PR status, the prognosis tended to become worse with c-erbB-2 amplification. It was demonstrated that the postoperative median survival of Stage I and II patients with amplification was similar to those of Stage III and IV patients without amplification (48 and 47.8 months). The postoperative median survival of node negative patients with amplification was shortened as compared to those of node positive ones without amplification (47.3 and 54 months). This observation indicates that c-erbB-2 amplification seems to be an useful independent prognosis indicator in breast cancer, particularly in identifying the subsets of high risk of recurrence in node negative or Stage I and II patients.

Blotting, Southern↗

PubMed1989

[Prognostic significance of progesterone receptor in breast cancer].

Estrogen and progesterone receptors (ER and PR) were detected in 400 women with primary breast cancer from 1979 to 1986. Cytosols showing saturable binding of 10 fmol/mg protein or more were taken as positive for ER and PR. The positive rate was 55.5% and 42.8%, respectively in this series. PR negative patients had higher risk of early recurrence than PR positive patients according to the highly significant difference between the two disease-free survival curves (P less than 0.01). The relative risk of recurrence in the PR negative group was 3.2 times higher than PR positive group (P less than 0.01). Simple ER positive or ER negative did not provide any relevant information for predicting the disease-free survival in this present series. Thirty months after mastectomy, 32.2% of the patients with PR negative tumors had recurrent disease as compared with the PR positive group (10.2%) (p less than 0.01). The recurrent rate was negatively correlated with tumor PR concentration. The prognostic value of PR status with respect to clinical stage, menopausal status and axillary node involvement is discussed. It is concluded that the PR content of breast cancer is an important predictor of prognosis and will help us to formulate treatment plan for the patients.

Adolescent↗